Literature DB >> 11369881

The role of the Type I interferon response in the resistance of mice to filovirus infection.

Mike Bray1.   

Abstract

Adult immunocompetent mice inoculated with Ebola (EBO) or Marburg (MBG) virus do not become ill. A suckling-mouse-passaged variant of EBO Zaire '76 ('mouse-adapted EBO-Z') causes rapidly lethal infection in adult mice after intraperitoneal (i.p.) inoculation, but does not cause apparent disease when inoculated subcutaneously (s.c.). A series of experiments showed that both forms of resistance to infection are mediated by the Type I interferon response. Mice lacking the cell-surface IFN-alpha/beta receptor died within a week after inoculation of EBO-Z '76, EBO Sudan, MBG Musoke or MBG Ravn, or after s.c. challenge with mouse-adapted EBO-Z. EBO Reston and EBO Ivory Coast did not cause illness, but immunized the mice against subsequent challenge with mouse-adapted EBO-Z. Normal adult mice treated with antibodies against murine IFN-alpha/beta could also be lethally infected with i.p.-inoculated EBO-Z '76 or EBO Sudan and with s.c.-inoculated mouse-adapted EBO-Z. Severe combined immunodeficient (SCID) mice became ill 3-4 weeks after inoculation with EBO-Z '76, EBO Sudan or MBG Ravn, but not the other viruses. Treatment with anti-IFN-alpha/beta antibodies markedly accelerated the course of EBO-Z '76 infection. Antibody treatment blocked the effect of a potent antiviral drug, 3-deazaneplanocin A, indicating that successful filovirus therapy may require the active participation of the Type I IFN response. Mice lacking an IFN-alpha/beta response resemble primates in their susceptibility to rapidly progressive, overwhelming filovirus infection. The outcome of filovirus transfer between animal species appears to be determined by interactions between the virus and the innate immune response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369881     DOI: 10.1099/0022-1317-82-6-1365

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  95 in total

1.  Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease.

Authors:  Matthew Frieman; Boyd Yount; Sudhakar Agnihothram; Carly Page; Eric Donaldson; Anjeanette Roberts; Leatrice Vogel; Becky Woodruff; Diana Scorpio; Kanta Subbarao; Ralph S Baric
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 2.  Filovirus vaccines.

Authors:  Steven B Bradfute; John M Dye; Sina Bavari
Journal:  Hum Vaccin       Date:  2011-06-01

3.  Assessment of rodents as animal models for Reston ebolavirus.

Authors:  Emmie de Wit; Vincent J Munster; Samia A Metwally; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

4.  Humanized Mice--A Neoteric Animal Disease Model for Ebola Virus?

Authors:  Joseph Prescott; Heinz Feldmann
Journal:  J Infect Dis       Date:  2015-11-17       Impact factor: 5.226

5.  Robust and sustained immune activation in human Ebola virus infection.

Authors:  Judith N Mandl; Mark B Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-07       Impact factor: 11.205

6.  The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR.

Authors:  Zongdi Feng; Melissa Cerveny; Zhipeng Yan; Bin He
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

Review 7.  Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

Authors:  Jin Huk Choi; Maria A Croyle
Journal:  BioDrugs       Date:  2013-12       Impact factor: 5.807

Review 8.  The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 2: Vaccine efficacy studies.

Authors:  Marko Zivcec; Christina F Spiropoulou; Jessica R Spengler
Journal:  Antiviral Res       Date:  2020-01-22       Impact factor: 5.970

9.  Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1.

Authors:  St Patrick Reid; Charalampos Valmas; Osvaldo Martinez; Freddy Mauricio Sanchez; Christopher F Basler
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

10.  Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway.

Authors:  James E Strong; Gary Wong; Shane E Jones; Allen Grolla; Steven Theriault; Gary P Kobinger; Heinz Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.